An interview with Dr. Harold Burstein from Dana Farber Cancer Institute in Boston, MA, chair on “Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast ...

Advances in molecular pathological classification have improved the depth of precision adjuvant treatment for metastatic breast cancer (MBC). The choice of endocrine therapy depends on the expression ...

Adding targeted therapy Kisqali (ribociclib) to the standard treatment plan can significantly reduce the risk of cancer ...

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations. Dr.

Endocrine therapy for breast cancer may reduce the risk of contralateral breast cancer (CBC). However, there are no published estimates quantifying the lifetime outcomes by age at primary diagnosis, ...

The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with ...

People with an underactive thyroid may have an increased risk of developing small intestinal bacterial overgrowth (SIBO), a risk that may be reduced with thyroid hormone treatment, according to a ...

Hormones are powerful chemical messengers that regulate many of the body's most important functions, including metabolism, ...

Comorbidity-specific recommendations will help those with contraindications to hormone the ...